{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-006475","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.666187+00:00","generated_at":"2026-06-16T19:19:36.401689+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Harmony Biosciences appoints Jeffrey Dayno as permanent President & CEO; Aronin returns to non-executive Chairman","bullets":["Dr. Jeffrey Dayno appointed President and CEO effective April 24, 2023; also joins Board as Class I director.","Dayno previously served as Interim President and CEO since Jan 6, 2023, and CMO since 2017.","Jeffrey Aronin returns from Executive Chairman to non-executive Chairman of the Board.","Dayno's employment agreement: base salary $650,000, target bonus 75% of base (up to 100% under certain circumstances).","Dayno stated WAKIX could be a $1B+ narcolepsy franchise with additional $1B potential from other indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-006475","json":"https://secwatch.observer/filing/0001558370-23-006475.json","markdown":"https://secwatch.observer/filing/0001558370-23-006475.md","text":"https://secwatch.observer/filing/0001558370-23-006475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/hrmy-20230424x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T19:19:36.401689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77c10d9887","claim":"Jeffrey M. Dayno was appointed as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"99e5a0a511","claim":"Jeffrey M. Dayno was appointed as Class I Director at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"Dr. Dayno has also been appointed to the Board as a Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"b12617cfe5","claim":"Jeffrey S. Aronin changed role as non-executive Chairman of the Board at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"returned to"},{"label":"Role","value":"non-executive Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}